Try our beta test site
2 studies found for:    ACY-1215 | lymphoma OR CLL
Show Display Options
Rank Status Study
1 Recruiting ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Condition: Recurrent Chronic Lymphoid Leukemia
Interventions: Drug: ACY-1215;   Drug: Ibrutinib;   Drug: Idelalisib
2 Active, not recruiting ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Conditions: Lymphoma;   Lymphoid Malignancies
Intervention: Drug: ACY-1215

Study has passed its completion date and status has not been verified in more than two years.